Slingshot members are tracking this event:
Ardelyx, Inc. Announces the Initiation of a Three Part Phase 3 Clinical Trial Evaluating RDX7675 In Patients with Hyperkalemia
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Jan 03, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Rdx7675, Potassium Binder, Hyperkalemia, Phase 3